According to the latest report by IMARC Group, titled "Smart Insulin Pens Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2028," the global smart insulin pens market reached a value of US$ 118.1 Million in 2022. Smart insulin pens are digital devices that help patients with diabetes manage insulin therapy. They work by allowing patients to track and monitor their insulin doses, making it easier to manage their blood glucose levels. The pens are equipped with Bluetooth or Wi-Fi connectivity, which allows them to be synced with a smartphone app or other electronic device. They offer several advantages over traditional insulin pens. One of the main benefits is that they help reduce the risk of hypoglycemia, a condition where the blood glucose level drops too low as the pens allow patients to monitor their insulin dosages more accurately, which can help prevent over- or under-dosing. In addition, smart pens help patients better understand their insulin requirements, which helps them make more informed decisions about their diabetes management. They offer a range of benefits over traditional insulin pens, including improved accuracy, better data tracking, and greater convenience.
Global Smart Insulin Pens Market Trends:
The global market is primarily driven by the increasing prevalence of diabetes. In line with this, the rapid adoption of digital smart health technologies is significantly contributing to the market growth. Furthermore, the rising need for more personalized diabetes management solutions is positively influencing the market. Apart from this, the presence of well-established healthcare systems and the escalating awareness of diabetes management are catalyzing the market. Moreover, the key players are investing in research and development to develop new and innovative smart insulin pen solutions that help improve diabetes management and patient outcomes. Additionally, the product's remote monitoring and data analysis capabilities and improved patient adherence to insulin therapy are strengthening the product demand. Some of the other factors driving the market growth include the development of user-friendly smart insulin pen devices, an increasing number of collaborations and partnerships between pharmaceutical companies and device manufacturers, heavy investment in research and development activities for diabetes management technologies, and favorable government initiatives to improve diabetes management and reduce healthcare costs. On account of the factors above, the market is anticipated to reach a value of US$ 193.2 Million by 2028, exhibiting a CAGR of 11.5% during 2023-2028.
- On the basis of the type, the market has been categorized into first generation pens and second generation pens.
- Based on usability, the market has been classified into prefilled and reusable.
- Based on indication, the market has been segmented into type 1 diabetes and type 2 diabetes.
- Based on connectivity, the market has been categorized into Bluetooth and USB.
- Based on end user, the market has been classified into hospitals and clinics, ambulatory surgical centers, and home care settings.
- On the basis of the region, the market has been divided into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others) and the Middle East and Africa.
- The competitive landscape of the market has been studied in the report with detailed profiles of the key players operating in the market. Some of the key players include Bigfoot Biomedical Inc., Digital Medics Pty Ltd., Emperra GmbH E-Health Technologies, Jiangsu Delfu Medical Device Co. Ltd., Medtronic plc, Novo Nordisk A/S, pendiq GmbH, Ypsomed AG.
|Base Year of the Analysis
||Type, Usability, Indication, Connectivity, End User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Bigfoot Biomedical Inc., Digital Medics Pty Ltd., Emperra GmbH E-Health Technologies, Jiangsu Delfu Medical Device Co. Ltd., Medtronic plc, Novo Nordisk A/S, pendiq GmbH and Ypsomed AG
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800